Skip to main content
main-content

15.05.2019 | Original Research Article | Ausgabe 3/2019

Targeted Oncology 3/2019

Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study

Zeitschrift:
Targeted Oncology > Ausgabe 3/2019
Autoren:
Masayuki Nakashima, Kazuki Ide, Koji Kawakami
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s11523-019-00642-8) contains supplementary material, which is available to authorized users.

Abstract

Background

The benefit of regorafenib for colorectal cancer patients was demonstrated in previous randomized studies. However, these studies showed a high rate of treatment-related adverse events, and adverse events were more common in Japanese patients. Some studies showed fewer adverse events and a longer survival time with a reduced initial dose. However, the benefits of a reduced initial dose of regorafenib have only been evaluated in small samples.

Objective

Our objective was to analyze the efficacy of initial regorafenib dose reduction compared with a standard dose for colorectal cancer patients.

Patients and methods

We used a hospital-based nationwide claims database. Patients who received regorafenib for metastatic colorectal cancer between June 2013 and July 2017 were included in this study. We divided the patients into a standard initial dose group (standard group) and a reduced initial dose group (reduced group). Overall survival (OS) and adverse events were compared between the two groups. We performed propensity score matching for sensitivity analysis.

Results

We included 2376 patients (1208 in the standard group and 1168 in the reduced group). The median OS was 12.3 months (95% confidence interval (CI): 11.0–13.3) in the standard group and 12.6 months (95% CI: 11.7–13.6) in the reduced group. A log-rank test showed no significant difference between the two groups (p = 0.41). Most adverse events occurred less frequently in the reduced group. In the sensitivity analysis, there was no significant difference for OS.

Conclusions

No significant difference was observed for OS between the standard group and the reduced group. However, there were fewer adverse events in the reduced group. The optimal initial dose of regorafenib should be identified in further studies.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt e.Med zum Sonderpreis bestellen!

Sichern Sie sich jetzt Ihr e.Med-Abo und sparen Sie 50 %!

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2019

Targeted Oncology 3/2019 Zur Ausgabe
  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.